FindTrial
Sign In

A real-world study of the efficacy and safety of genetically recombinant human growth hormone in the treatment of children with growth hormone deficiency meeting the diagnostic criteria of the current guidelines in China

A real-world study of the efficacy and safety of genetically recombinant human growth hormone in the treatment of children with growth hormone deficiency meeting the diagnostic criteria of the current guidelines in China

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300078240
Enrollment
Unknown
Registered
2023-12-01
Start date
2023-12-01
Completion date
Unknown
Last updated
2023-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

growth hormone deficiency

Interventions

GHD group:NA

Sponsors

Fuzhou Children's Hospital of Fujian Province
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 18 Years

Inclusion criteria

Inclusion criteria: Meets diagnostic criteria for growth hormone deficiency.

Exclusion criteria

Exclusion criteria: (1) the presence of severe organic pathology; (2) the presence of severe congenital diseases or hepatic or renal hypoplasia; (3) the presence of drug allergic reactions to growth hormone; (4) the recent use of medications that affect the growth of the child.

Design outcomes

Primary

MeasureTime frame
Insulin-like growth factor 1;—

Secondary

MeasureTime frame
Height standard deviation;Height growth rate;—

Countries

China

Contacts

Public ContactRuimin Chen

Fuzhou Children's Hospital of Fujian Province

chenrm321@sina.com+86 136 0082 6683

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026